Project Grant R35HL177136
Award Date
4/15/25
Completion Date
3/31/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Institutes of Health's National Heart, Lung and Blood Institute awarded $2,350,623 under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota on May 1, 2021 for a project concluding on April 30, 2022. The project aims to reduce childhood obesity through an individual randomized controlled trial testing combinations of ecological momentary intervention, home visiting, and video feedback delivered to 510 low-income, racially...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $760,403 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New York University School of Medicine to study the long-term population-level impact of a school-based parenting-focused intervention to prevent obesity among Black and Latinx children in historically disinvested neighborhoods. The 5-year project, starting on July 1, 2024, will evaluate the intervention's impact on obesity (BMI) trajectories in...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $774,229 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Kaiser Foundation Hospitals of Oakland, CA. The purpose of this 4-year grant, awarded on February 1, 2025, is to conduct a large longitudinal cohort study to better understand the epidemiology of cardiometabolic conditions (e.g. hypertension, prediabetes, type 2 diabetes) among a...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $171,450 to The General Hospital Corporation (doing business as Massachusetts General Hospital) from September 1, 2024 to August 31, 2026. The project aims to investigate the biological mechanisms linking excess body fat (adiposity) and elevated blood lipid levels, which are major risk factors for cardiovascular disease. Specifically, the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $117,750 to Arizona State University (ASU) to conduct a longitudinal study investigating the prospective relationships between neighborhood environment features and physical activity and weight status across different age groups. The study aims to leverage data from five existing NIH-funded studies to examine how baseline...
The University of Michigan was awarded a $691,124 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to test the hypothesis that persistent circadian disruption, including misaligned sleep, eating, and activity timing, will be related to the development of cardiometabolic risk from adolescence to young adulthood. The project will leverage existing objective sleep/wake pattern and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $181,980 to the University of Colorado-Denver to investigate the relationship between epicardial adipose tissue (EAT) and cardiometabolic health in youth with type 2 diabetes. The research aims to determine if MRI-assessed EAT in youth with type 2 diabetes correlates with cardiometabolic risk factors, independent of BMI. It will...
This federal Project Grant award, valued at $1,399,182.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 1, 2024, supports a comprehensive research study to investigate early-life risk factors and underlying mechanisms for the development of adult coronary heart disease (CHD). The primary objectives are to: 1) identify which small-for-gestational-age (SGA) infants are at elevated risk for later-life CHD and cardiovascular...
This federal Project Grant award of $121,500.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to investigate molecular mechanisms linking environmental/lifestyle risk factors to cardiovascular traits and disease risk. The research aims to quantify the extent to which DNA methylation and gene expression mediate these relationships, leveraging multi-omics data from the NHLBI Trans-Omics for Precision...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to delineate adipose tissue topography and identify novel signaling or cell populations as therapeutic targets for obesity-associated inflammation. The $115,949 award, effective September 1, 2024 through August 31, 2026, will be used by the awardee, The Regents of the University of California, San Francisco...